Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 6/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | GALR3 | O60755 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2797912 | 0.83 | KDM4E (0.42) | LMNASMN1; SMN2MAPTTDP1L3MBTL1 | |
| SCHEMBL157144 | 0.79 | TSHR (0.37) | SMN1; SMN2HPGDALOX15POLBALDH1A1 | |
| SCHEMBL2799841 | 0.74 | ALDH1A1 (0.44) | LMNASMN1; SMN2MAPTNPSR1TDP1 | |
| SCHEMBL19362158 | 0.72 | POLB (0.34) | TDP1HPGDALOX15POLBKDM4E | |
| SCHEMBL8324702 | 0.72 | PTGS1 (0.57) | LMNASMN1; SMN2MAPTNPSR1TDP1 | |
| SCHEMBL6580109 | 0.71 | PTPN9 (0.34) | TDP1HPGDALOX15POLBALDH1A1 | |
| SCHEMBL9744811 | 0.71 | HPGD (0.48) | LMNASMN1; SMN2MAPTNPSR1TDP1 | |
| SCHEMBL10465166 | 0.69 | TAAR1 (0.40) | LMNAMAPTTDP1L3MBTL1KMT2A | |
| SCHEMBL4663927 | 0.68 | KMT2A (0.35) | LMNATDP1L3MBTL1HPGDKMT2A | |
| SCHEMBL27538650 | 0.67 | CA1 (0.41) | HPGDALOX15CES2GALR3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1005327-A1 | TARGETED LIPOSOMAL CONSTRUCTS FOR DIAGNOSTIC AND THERAPEUTIC USES | SDG, INC. (US) | 2000-06-07 | — | — | EP | claimed |
| EP-0999855-A1 | POLYMER BASED PHARMACEUTICAL COMPOSITIONS FOR TARGETED DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | SDG, Inc. (US) | 2000-05-17 | — | — | EP | claimed |
| US-6063400-A | CARRIER; DIAGNOSTIC OR THERAPEUTIC AGENT AND SEQUESTERING AGENT | SDG, INC. (US) | 2000-05-16 | — | — | US | claimed |
| WO-1999004824-A1 | POLYMER BASED PHARMACEUTICAL COMPOSITIONS FOR TARGETED DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | SDG, INC. (US) | 1999-02-04 | — | — | WO | claimed |
| WO-1999001110-A1 | TARGETED LIPOSOMAL CONSTRUCTS FOR DIAGNOSTIC AND THERAPEUTIC USES | SDG, INC. (US) | 1999-01-14 | — | — | WO | claimed |
| EP-0274467-B1 | HEPATOCYTE DIRECTED VESICLE DELIVERY SYSTEM | GEHO, W., Blair (US) | 1992-05-20 | — | — | EP | claimed |
| US-10751418-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20200261363-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG INC (US) | 2020-08-20 | — | — | US | disclosed |
| US-10568835-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10004686-B2 | Lipid construct for delivery of insulin to a mammal | SDG, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-9943602-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9145453-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9034372-B2 | Lipid construct for delivery of insulin to a mammal | SDG, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| EP-0999855-A1 | POLYMER BASED PHARMACEUTICAL COMPOSITIONS FOR TARGETED DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | SDG, Inc. (US) | 2000-05-17 | — | — | EP | disclosed |
| US-6063400-A | CARRIER; DIAGNOSTIC OR THERAPEUTIC AGENT AND SEQUESTERING AGENT | SDG, INC. (US) | 2000-05-16 | — | — | US | disclosed |
| WO-1999059545-A9 | TARGETED LIPOSOMAL DRUG DELIVERY SYSTEM | SDG INC (US) | 2000-04-27 | — | — | WO | disclosed |
| WO-1999059545-A1 | TARGETED LIPOSOMAL DRUG DELIVERY SYSTEM | SDG, INC. (US) | 1999-11-25 | — | — | WO | disclosed |
| WO-1999004824-A1 | POLYMER BASED PHARMACEUTICAL COMPOSITIONS FOR TARGETED DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | SDG, INC. (US) | 1999-02-04 | — | — | WO | disclosed |
| WO-1999001110-A1 | TARGETED LIPOSOMAL CONSTRUCTS FOR DIAGNOSTIC AND THERAPEUTIC USES | SDG, INC. (US) | 1999-01-14 | — | — | WO | disclosed |
| US-4603044-A | USING CONNECTOR MOLECULE HAVING HYDROPHILIC AND CIPOPHILIC PORTIONS FOR TARGETER DRUG DELIVERY | TECHNOLOGY UNLIMITED, INC. (US) | 1986-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10568835-B2 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | LMNA 1568/4885SMN1; SMN2 3997/4885MAPT 3275/4885 |
| US-10004686-B2 | Lipid construct for delivery of insulin to a mammal | INSR, IAPP, GPR119 | LMNA 1192/4885SMN1; SMN2 3786/4885MAPT 3999/4885 |
| US-20200261363-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | INSR, IAPP, GPR119 | LMNA 1192/4885SMN1; SMN2 3786/4885MAPT 3999/4885 |
| US-10751418-B2 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | LMNA 1568/4885SMN1; SMN2 3997/4885MAPT 3275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.